References
- World Health Organisation. Report on the Second intercountry meeting on health technology assessment: guidelines on the establishment of programmes within national health system Washington (DC): WHO; [cited 2021 July 13]. Available from: https://applications.emro.who.int/docs/IC_Meet_Rep_2015_16354_en.pdf?ua=1.
- United Nations Children’s Emergency Fund. Levels & Trends in Child Mortality. UNICEF. 2020. [cited 14 July 2021]. Available from: https://www.unicef.org/reports/levels-and-trends-child-mortality-report-2020.
- Levine MM, Nasrin D, Acácio S, et al. Diarrhoeal disease and subsequent risk of death in infants and children residing in low-income and middle-income countries: analysis of the GEMS case-control study and 12-month GEMS-1A follow-on study. Lancet Glob Health. 2020;8(2):e204–e214.
- Global Burden of Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018;18(11):1211–1228.
- Fischer TK, Duc Anh D, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in vietnam. J Infect Dis. 2005;192(10):1720–1726.
- Vu Nguyen T, Le Van P, Le Huy C, et al. Etiology and epidemiology of diarrhea in children in Hanoi, Vietnam. Int J Infect Dis. 2006;10(4):298–308.
- Abdel-Aziz1 SB, Mowafy MA, Galal YS. Assessing the impact of a community-based health and nutrition education on the management of diarrhea in an urban district, cairo, Egypt. Glob J Health Sci. 2015;8(2):46–55.
- The World Bank. Diarrhea Treatment Percentage of Children Under 5 Who Received Oral Rehydration Solution Packet. Country Indicators [cited 2022. January 19]. Available from: https://data.worldbank.org/indicator/SH.STA.ORTH.
- Central Agency for Public Mobilization and Statistics (CAPMAS), Egypt. Population Demographics. [cited 2020. July 19]. Available from http://www.capmas.gov.eg/.
- Haut Commissariat au Plan (HPC) Morocco. Population Demographics. [cited 2020. July 16]. Available from: www.hcp.ma.
- Philippine Statistics Authority. [cited 2020. July 13]. Available from: https://psa.gov.ph/sites/default/files/attachment/hsd/pressrelease/Table4_9.pdf.
- Armon K, Lakhanpaul M, Stephenson T. An evidence and consensus based guideline for acute diarrhoea management. Arch Dis Child. 2002;86(2):138.
- World Health Organization (WHO). The treatment of diarrhoea – a manual for physicians and other senior health workers. 2005. [cited 14 July 2021]. Available from: https://apps.who.int/iris/handle/10665/43209.
- National Institute for Health and Clinical Excellence (NICE). Diarrhoea and vomiting caused by gastroenteritis – diagnosis, assessment and management in children younger than 5 years. 2009. [cited 14 July 2021]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK63844/.
- El-Khayat H, El-Hodhod M, Gad S, et al. Management of acute gastroenteritis in children below five years by general practitioners: an egyptian consensus. J Gastrointest Dig Syst. 2021;11(5):2–8.
- PhilHealth Website. PhilHealth Circular No 2016-001. Policy statement on the Diagnosis and Management of Acute Gastroenteritis as reference by the Corporation in ensuring quality of care. 2016. [cited 14 July 2021]. Available from: https://www.philhealth.gov.ph/circulars/2016/circ2016-001.pdf.
- Philippines Department of Health. Philippine National Formulary Manual for Primary Healthcare 8th Edition. Manila: Philippines, 2014. [cited 14 July 2021]. Available from: https://caro.doh.gov.ph/wp-content/uploads/2018/04/PNF-Manual-for-Primary-Healthcare.pdf.
- Philippines Department of Health. Adoption of the National Food and Waterborne Disease Prevention and Control Program Clinical Practice Guideline on Acute Infectious Diarrhea Reference Manual Department Circular 2019-0233. 2019. [cited 14 July 2021]. Available from: https://doh.gov.ph/sites/default/files/publications/FWBD%20MOP%202019.pdf.
- Sultana R, Luby S, Gurley ES, et al. Cost of illness for severe and non-severe diarrhea borne by households in a low-income urban community of Bangladesh: a cross-sectional study. PLOS Negl Trop Dis. 2021;15(6):e0009439.
- At Thobari J, Sutarman Mulyadi AWE, et al. Direct and indirect costs of acute diarrhea in children under five years of age in Indonesia: health facilities and community survey. Lancet Reg Health West Pac. 2022;19:100333.
- Barakat A, Halawa EF. Household costs of seeking outpatient care in Egyptian children with diarrhea: a cross-sectional study. Pan Afr Med J. 2013;14:42.
- Hasan MZ, Mehdi GG, De Broucker G, et al. The economic burden of diarrhea in children under 5 years in Bangladesh. Int J Infect Dis. 2021;107:37–46.
- Health Technology Assessment Unit, Department of Health Philippines. Philippine Health Technology Assessment Methods Guide. Methodological standards in evaluation of health technologies in the Philippines. First Edition. 2020. [cited 14 July 2021]. Available from: https://doh.gov.ph/sites/default/files/health_advisory/HTA%20Methods%20Guide_Public%20Consultation%2003.2020_1.pdf.
- Elsisi GH, Kalo Z, Eldessouki R, et al. Recommendations for reporting pharmacoeconomic evaluations in Egypt. Value Health Reg Issues. 2013;2(2):319–327.
- Farid S, Elmahdawy M, Baines D. A systematic review on the extent and quality of pharmacoeconomic publications in Egypt. Clin Drug Investig. 2019;39(2):157–168.
- Tran BX, Nong VM, Maher RM, et al. A systematic review of scope and quality of health economic evaluation studies in vietnam. PLOS One. 2014;9(8):e103825.
- Alefan Q, Rascati K. Pharmacoeconomic studies in world health organisation Eastern Mediterranean countries: reporting completeness. Int J Technol Assess Health Care. 2017;33(2):215–221.
- Khoudri I, Belayachi J, Dendane T, et al. Measuring quality of life after intensive care using the arabic version for Morocco of the EuroQol 5 dimensions. BMC Res Notes. 2012;5(1):56.
- Griffin AE, Ragab G, Ziada S, et al. Setting recommendations for good practice of health technology assessment in the Egyptian ministry of health. Value in Health. 2016;19(7):A497.
- Griffiths UK, Legood R, Pitt C. Comparison of economic evaluation methods across low-income, middle-income and high-income countries: What are the differences and why? Health Econ. 2016;25(Suppl 1):29–41.
- Researchgate. 2017. News Across Asia. Health Technology Assessment and Its Application in Vietnam. [cited July 13 2021]. Available from: https://www.researchgate.net/profile/Tuan-Kieu/publication/318351014_Health_Technology_Assessment_and_Its_Application_in_Vietnam/links/59e045890f7e9bc512589519/Health-Technology-Assessment-and-Its-Application-in-Vietnam.pdf.
- Vo TQ. Health technology assessment in developing countries: a brief introduction for vietnamese health-care policymakers. Asian J Pharm. 2018;12(1). DOI:10.22377/ajp.v12i01.2340
- Sharma M, Teerawattananon Y, Dabak SV, et al. A landscape analysis of health technology assessment capacity in the association of South-East Asian Nations Region. Health Res Policy Syst. 2021;19(1):19.
- Wilkinson T, Sculpher M, Claxton K, et al. The international decision support initiative reference case for economic evaluation: an aid to thought. Value Health. 2016;19(8):921–928.
- World Health Organisation. WHO. 2015 Global Survey on Health Technology Assessment by National Authorities. Geneva Switzerland. 2015. [cited 13 July 2021]. Available from: https://www.who.int/health-technology-assessment/MD_HTA_oct2015_final_web2.pdf.
- Manca A, Willan AR. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics. 2006;24(11):1101–1119.
- Mullins DC, Onwudiwe NC, de Aruajo GTB, et al. Guidance document: global pharmacoeconomic model adaption strategies. Value Health Reg Issues. 2014;5:7–13.
- Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12(4):409–418.
- Matheson AJ, Noble S. Racecadotril. Drugs. 2000;59(4) :829–35. discussion 836:–7.
- European Medicines Agency (EMA). List of Nationally Authorised Medicinal Products. [cited 2022. January 20]. Available from: https://www.ema.europa.eu/en/documents/psusa/racecadotril-list-nationally-authorised-medicinal-products-psusa/00002602/202003_en.pdf.
- Rautenberg TA, Zerwes U, Foerster D, et al. Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model. Clinicoecon Outcomes Res. 2012;4:109–116.
- Rautenberg TA, Zerwes U. The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand. CEOR. 2017;9:411–422.
- Rautenberg TA, Zerwes U, Lee WS. Cost utility, budget impact, and scenario analysis of racecadotril in addition to oral rehydration for acute diarrhea in children in Malaysia. Clinicoecon Outcomes Res. 2018;10:169–178.
- Lehert P, Cheron G, Alvarez Calatayud G, et al. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. Dig Liver Dis. 2011;43(9):707–713.
- Alvarez Calatayud E, Pinei Simon G, Taboada Castro L, et al. Efectividad de racecadotrilo en el tratamiento de la gastroenteritis aguda [the effectiveness of racecadotril in the treatment of acute gastroenteritis]. Acta Pediatr.Esp. 2009;67(3):117–122.
- Baumer P, Joulin Y. Pre- and postmarketing safety profiles of racecadotril sachets, a “new” antidiarrhoeal drug. J Pediatr Gastroenterol Nutr. 2009;48(Suppl 3):E99.
- Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J. Med Econ. 2008;11(3):471–484.
- Kind P, Hardman G, Macran S. UK population norms for EQ-5D, discussion paper 172. Centre for Health Economics York University; 1999. Available from: https://www.york.ac.uk/che/pdf/DP172.pdf
- Eberlin M, Chen M, Mueck T, et al. Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials. BMC Pediatr. 2018;18(1):124.
- International Society for Pharmacoeconomic Outcomes Research ISPOR. Pharmaceconomic Guidelines Around the World, Egypt. 2021. [cired 14 July 2021]. Available from: https://tools.ispor.org/PEguidelines/countrydet.asp?c=39&t=1.
- PhilHealth Website. Annex A. List of Medical Case Rates. 2017. [cited 14 July 2021]. Available from: https://www.philhealth.gov.ph/circulars/2017/annexes/0019/AnnexA-MedicalCaseRates.pdf.
- Rochanathimoke O, Riewpaiboon A, Postma MJ, et al. Health related quality of life impact from rotavirus diarrhea on children and their family caregivers in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018;18(2):215–222.
- Thorrington D, Eames K. Measuring health utilities in children and adolescents: a systematic review of the literature. PLOS One. 2015;10(8):e0135672.
- Ungar WJ. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated? Pharmacoeconomics. 2011;29(8):641–652.
- Janssen MF, Szende A, Cabases J, et al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205–216.